Wells Fargo & Company Annovis Bio, Inc. Call Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ANVS
# of Institutions
47Shares Held
946KCall Options Held
642KPut Options Held
1.57M-
Vanguard Group Inc Valley Forge, PA361KShares$3.15 Million0.0% of portfolio
-
Black Rock Inc. New York, NY101KShares$879,1890.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA100KShares$873,0000.0% of portfolio
-
Geode Capital Management, LLC Boston, MA76.2KShares$665,5140.0% of portfolio
-
Wescott Financial Advisory Group, LLC41.6KShares$363,2290.03% of portfolio
About Annovis Bio, Inc.
- Ticker ANVS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 8,163,920
- Market Cap $71.3M
- Description
- Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...